• In this study we examined a possible association between

  2019-09-07

  

  In this study, we examined a possible association between the 19-bp KPT-9274 kinase and the 9-bp repeat in the DHFR gene and the risk of spina bifida in 121 mothers of a spina bifida affected child, 292 control women, 109 spina bifida patients and 234 pediatric controls using a case-control design.

• In this clinical context measures of cell mediated immune

  2019-09-06

  

  In this clinical context, measures of cell-mediated immune response to CMV have been evaluated. The QuantiFERON-CMV assay (QFN-CMV; Qiagen, Germany) which measures predominantly CD8+ T-cell responses to CMV by an in-tube IFN-gamma release technique is commercially available in some regions.1, 2 Cons

• Enolase as a plasminogen receptor and activator localized on

  2019-09-06

  

  Enolase, as a plasminogen receptor and activator localized on the surface of several helminths, can interact with the host fibrinolytic system (Yang et al., 2010, Du et al., 2009, de la Torre-Escudero et al., 2010). The enzyme is also one of excretory/secretory (ES) products in some helminths, such

• 2\'-O-Methyl-ATP Plasminogen is composed of five

  2019-09-06

  

  Plasminogen is composed of five N-terminal kringle domains and a C-terminal serine protease domain. The kringle domains have an affinity to lysine and binding of plasminogen with its receptors is dependent on its lysine interacting kringle domains [10], [28]. In the current report, we show that enol

• The redox sensitive transcription factor NF B is

  2019-09-06

  

  The redox sensitive transcription factor NF-κB is reported to play a crucial role in the COPD pathogenesis via up regulating the expression of several cytokines, chemokines, growth factors, and adhesion molecules [71]. Incidentally, we and others have shown that PARP-1 modulates the NF-κB activation

• gap-27 ELUXA HM EMSI is an ongoing pivotal Phase II global

  2019-09-06

  

  ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp

• enzastaurin kinase br Results br Discussion The process by w

  2019-09-06

  

  Results Discussion The process by which MBCs differentiate from GC B cell precursors remains mostly uncharacterized, in large part because of the uncertainty surrounding the nature of the precursor enzastaurin kinase within the GC. The identification here of a distinct subset of GC B cells, C

• br Experimental Procedures br Author Contributions br Acknow

  2019-09-06

  

  Experimental Procedures Author Contributions Acknowledgments We thank the Mouse Modeling, Integrated Microscopy, and FACS Facilities of IGB-CNR, Naples. Dr. Laura Pisapia is acknowledged for flow cytometry analyses. We are grateful to Prof. Chris Ponting and George A. Calin for insightful s

• A different example of substrate dependent activation

  2019-09-06

  

  A different example of substrate-dependent activation is seen in CSN5, a JAMM-type DUB found in the eight subunit COP9 signalosome (CSN) [34]. The CSN deconjugates NEDD8 (neural precursor cell expressed developmentally downregulated 8) from Cullin Ring ubiquitin E3 ligases (CRLs). Through this activ

• We found that the postnatal

  2019-09-06

  

  We found that the postnatal absence of norepinephrine yields differing effects depending on noradrenergic receptor type and bungarotoxin region. The density of α1-AR, indicated by [3H]prazosin binding was similar between Dbh+/− and Dbh−/− mice except for a significant increase in hippocampus in Dbh

• br Acknowledgements We thank Dr James Ritchie

  2019-09-06

  

  Acknowledgements We thank Dr. James Ritchie and his dedicated staff (Deptartment of Pathology, Emory University) for performing measures of serum VPA levels; Sumitomo Pharmaceuticals (Osaka, Japan) for the generous donation of DOPS, which is required for breeding Dbh −/− mice; Pfizer (Sandwich, K

• During the past three decades platinum based

  2019-09-06

  

  During the past three decades, platinum-based DNA-alkylating agents have been employed in the treatment of various cancers [14]. Oxaliplatin is currently used as a first-line treatment for colorectal cancer (CRC) [15]. Unfortunately, a large portion of CRC patients receiving oxaliplatin-based chemot

• This work was supported by grants from

  2019-09-06

  

  This work was supported by grants from the Institute of Cancer Research (ICR) and Biotechnology and Biological Sciences Research Council (BB/I014276/1 and BB/M013782/1). Main Text In 2006, Warburg et al. described an apparently distinct connective-tissue disorder characterized by blepharophimosi

• br Results and discussion br Conclusion Novel

  2019-09-06

  

  Results and discussion Conclusion Novel and selective aziridine-based inhibitors for the Leishmania mexicana protease LmCBP2.8 were discovered. Compounds 7d (Ki = 0.8 μM), 9d (Ki = 1.36 μM), 12d (Ki = 0.77 μM), 14d (Ki = 0.9 μM) and 18 (Ki = 0.441 μM) showed the highest potency and selectivity

• Introduction Cytochrome P CYP A is the most

  2019-09-06

  

  Introduction Cytochrome P450 (CYP)3A is the most important enzyme involved in the metabolism of 30–40% of currently prescribed drugs [1]. The Zotarolimus level and activity of CYP3A show large intra- and inter-individual variability, which contributes to unpredictable drug response and toxicity. A

15645 records 967/1043 page Previous Next First page 上5页 966967968969970 下5页 Last page